The PSMA-11-derived hybrid molecule PSMA-914 specifically identifies prostate cancer by preoperative PET/CT and intraoperative fluorescence imaging

Resection of tumor tissue represents one of the standard curative treatment options for the clinical management of prostate cancer. However, intraoperative localization and precise delineation of malignant tissue from surrounding healthy structures still remain challenging. The development of PSMA-targeting hybrid molecules enabling the pre- and intraoperative detection of tumor tissue supported by both radioactivity (e.g., using DROP-IN technology) and fluorescence might help to overcome these limitations. Here, we report for the first time preoperative PET/CT imaging and subsequent fluorescence-guided surgery aided by a PSMA-11-derived peptidomimetic PSMA-targeting hybrid molecule.